Podcasts about Coronary

Heart disease often develops silently for decades before symptoms ever appear, which is why early detection can be one of the most powerful tools for protecting long-term health and longevity.     On today's show, I break down the Coronary Artery Calcium (CAC) Score, also known as the Agatston Score, and why it may be one of the most important cardiovascular screening tools for adults over 40.     We'll explore what this scan measures, how the scoring system works, and what different score ranges may reveal about your future heart disease risk.     I'll also explain the limitations of the test, why plaque buildup can begin long before symptoms arise, and how lifestyle, inflammation, blood sugar balance, and other health markers all play a role in cardiovascular health.     Most importantly, you'll learn why prevention and early awareness matter so much, and how foundational health habits may help support long-term heart health and healthy aging.     So join me on today's Cabral Concept 3772 as we take a closer look at the CAC Score and what it may reveal about your cardiovascular health and longevity.   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3772 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Heart disease often develops silently for decades before symptoms ever appear, which is why early detection can be one of the most powerful tools for protecting long-term health and longevity.     On today's show, I break down the Coronary Artery Calcium (CAC) Score, also known as the Agatston Score, and why it may be one of the most important cardiovascular screening tools for adults over 40.     We'll explore what this scan measures, how the scoring system works, and what different score ranges may reveal about your future heart disease risk.     I'll also explain the limitations of the test, why plaque buildup can begin long before symptoms arise, and how lifestyle, inflammation, blood sugar balance, and other health markers all play a role in cardiovascular health.     Most importantly, you'll learn why prevention and early awareness matter so much, and how foundational health habits may help support long-term heart health and healthy aging.     So join me on today's Cabral Concept 3772 as we take a closer look at the CAC Score and what it may reveal about your cardiovascular health and longevity.   - - - For Everything Mentioned In Today's Show: StephenCabral.com/3772 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

Commentary by Dr. Jian'an Wang.

In this episode of The Atrium, host Dr. Alice Copperwheat speaks with Dr. Elan Burton, clinical associate professor in the Department of Cardiothoracic Surgery at the Stanford University School of Medicine and Section Chief for Stanford Medicine Affiliates, about distal coronary anastomosis. Chapters  00:00 Intro  01:08 Why CT Surgery?  03:01 Overview & History  05:02 Geometric Planning & Hemodynamics  10:40 Sequential & Composite Configurations  16:23 Y or T Grafts  21:21 Step-by-Step, Suturing  30:37 Endarterectomy  36:37 Intraop Quality Assurance  40:29 Failed Mechanisms & Pitfalls  43:18 Future Trends  45:54 Summary  47:03 Surgery Training Advice  They discuss the history of distal coronary anastomosis, geometric planning, and hemodynamics, as well as sequential grafting and composite configurations, including Y and T grafts. The conversation also covers arteriotomy, suturing techniques, and the continuous parachute method. Additionally, they delve into the traction technique, open direct vision, and intraoperative quality assurance, including pulsatility index. Furthermore, they examine failure mechanisms such as graft kinking and explore future trends. The Atrium is a monthly podcast presenting clinical and career-focused topics for residents and early career professionals across all cardiothoracic surgery subspecialties. Keep an eye out for next month's episode. Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

With Edoardo Conte and Daniele Andreini, Galeazzi-Sant'Ambrogio Hospital IRCCS, Milan - Italy and Gal Tsaban, Mayo Clinic, Rochester - USA. Link to paper Link to editorial

This week we review a recent work from the CT group at NY Presbyterian assessing the impact of phenylephrine during pediatric congenital CT scans to lower heart rate. Why is a lower heart rate better for CCT's? Should this agent be routinely employed for this indication during CT scans in children? Dr. Yosef Cohen, pediatrics resident at the Children's Hospital at Montefiore shares his insights from a recent work he co-authored. doi: 10.1093/ehjimp/qyag023. eCollection 2025 Aug.

In this sponsored episode from Novartis Pharmaceuticals Corporation, a leading preventive cardiologist walks through the 2026 cholesterol guideline update and what it means in practice. Seth J. Baum, a Columbia-trained preventive cardiologist, founder of Flourish Research, chairman of the Family Heart Foundation, and past president of the American Society of Preventive Cardiology, breaks down the major changes in the March 2026 ACC and AHA guideline release. You will hear why LDL targets are explicit again after nearly a decade, why universal lipoprotein A screening is now recommended, why a coronary calcium score above 300 places a patient in the highest-risk treatment tier, and why apolipoprotein B measurement can refine risk assessment when LDL is at goal. Baum also covers the alternatives available when a patient cannot tolerate a statin, including ezetimibe, PCSK9 inhibitors, inclisiran, and bempedoic acid, along with practical framing for the statin-hesitant patient. You will also hear his approach to discussing cholesterol with patients, from the science of lipoprotein physiology to the case for earlier and more aggressive lipid-lowering treatment. Dr. Baum was not compensated for his participation in today's episode. The opinions expressed are his alone and do not represent the opinions of Novartis Pharmaceuticals Corporation. At Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We're proud of the positive impact we've made over the past 40 years and remain dedicated to tackling the most challenging problems in CVD. Through cutting-edge science and technology, we are focusing on areas of high unmet need, including scaling our xRNA platform across multiple risk factors and pioneering breakthroughs for genetically driven CVD risk factors and common heart conditions, including atrial fibrillation. We also work with patients, healthcare professionals, and organizations around the world to improve CV care beyond medicine alone. Together, we can help people with CVD enjoy longer, healthier lives and more time with their loved ones. Learn more here: https://Novartis.us/cardiovascular-disease VISIT SPONSOR → https://Novartis.us/cardiovascular-disease SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

How do you turn your patients' calcium scores into clear, personalized prevention plans? Credit available for this activity expires: 4/28/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/episode-two-cracking-code-coronary-artery-calcium-cac-2026a1000clt?ecd=bdc_podcast_libsyn_mscpedu

Paclitaxel-coated Versus Uncoated Balloon For Coronary In-stent Restenosis - Three-year Outcomes Of The Agent Ide Trial

Commentary by Dr. Elvin Kedhi.

Send us Fan MailIn this episode, we break down everything you need to know about coronary angiography. Written by: Dr. Luke MacLeod. Reviewed by: Drs. Michael Ward and Alison Lai.Support the show

INNOVATION COMPETITION: Retrievable Scaffold Therapy: The Spur Elute Coronary Retrievable Scaffold System

Coronary CT Angiograms for Heart Disease Screenings, Health Insurance Deregulation, Hagler-Leonard by Tommy McElroy

In this episode, we explore how REBOA can become an integrated tool for deliberate physiologic support in profound shock. REBOA is a word that immediately commands attention in pre-hospital care. For many teams, it represents the edge of capability, a high-stakes intervention reserved for catastrophic haemorrhage and profound shock.  Many clinicians still think of it primarily as a haemorrhage-control device: inflate fully, plug the leak, and hope for the best. But in profound shock, bleeding is only part of the problem. Coronary perfusion hinges on proximal aortic diastolic pressure, and if the heart isn't being perfused, everything else we do is on borrowed time. Today's guests, Dr Jon Barratt and Dr Halden Hutchinson-Bazely, sit at the cutting edge of this shift in thinking. Jon is a Consultant in Emergency Medicine and Pre-Hospital Emergency Medicine with the British Army and the NHS, serving as Clinical Lead for Research and Clinical Innovation at Yorkshire Air Ambulance and as a MERIT Consultant with West Midlands Ambulance Service. He is a Senior Lecturer with the Academic Department of Military Emergency Medicine and a founding force behind the SPEAR programme, a resuscitation training initiative that leverages ultrasound-guided arterial access and physiologic targets to support patients in deep shock. Jon was also principal investigator for the ERICA-ARREST trial, investigating the use of REBOA to augment coronary perfusion in out-of-hospital cardiac arrest. Hutch is a pre-hospital care doctor at London's Air Ambulance (LAA), specialising in exsanguination, and an intensive care doctor at St Bartholomew's Hospital, specialising in ECMO. He is practising in endovascular resuscitation across the spectrum of the medical and trauma fields. Together with Jon, he is a SPEAR and EVTM faculty member and was an investigator for ERICA-ARREST. He brings a thoughtful and clinically grounded perspective to trauma management, with a focus on practical decision-making in high-pressure environments. His work reflects a commitment to evidence-informed practice and continual learning within acute care systems.You can find more on SPEAR here: https://journals.sagepub.com/doi/10.1177/11297298241242157And here: https://www.eaaa.org.uk/what-we-do/research-and-education/clinical-education/spear 

From Clinical Need to Market: How Medical Devices Are Built w/ Stuart Broyles of MDM2 - AZ TRT S07 EP06 (288) 3-29-2026       What We Learned This Week:  Medical devices can take a decade to reach patients Bringing a medical device to market isn't quick. Phoenix is quietly becoming a major MedTech hub The Valley has a growing cluster of medical technology companies including: The biggest risk in medical innovation is building something doctors don't need One of the most common failures in MedTech is creating technology without validating the clinical problem first. Universities often invent the technology—but companies bring it to life Many medical device ideas originate in research labs. The future of healthcare innovation depends on collaboration Successful medical device innovation requires an ecosystem     Guest: Stuart Broyles, PhD LKIN: https://www.linkedin.com/in/stuart-broyles-phd/   Stuart builds connections that move ideas forward—from university research to real-world MedTech solutions. He was at WL Gore & Assoc. for nearly 3 decades working in MedTech at various levels and helped bring 13 devices to market. Also includes, university advisory roles, early-stage venture coaching, and innovation ecosystem development. Organization: MDM2 (Medical Device Manufacturing Multiplier)   Summary:  Medical devices can take a decade to reach patients Bringing a medical device to market isn't quick. While some devices can launch in six months to a year, many take five to ten years once clinical trials and regulatory approvals are involved. That's why early testing and feedback are critical. Phoenix is quietly becoming a major MedTech hub The Valley has a growing cluster of medical technology companies including: ·         Medtronic ·         Abbott Laboratories ·         Dexcom ·         West Pharmaceutical Services Add in research from Arizona State University and University of Arizona and the region is building a strong bioscience ecosystem. The biggest risk in medical innovation is building something doctors don't need One of the most common failures in MedTech is creating technology without validating the clinical problem first. Organizations like MDM2 (Medical Device Manufacturing Multiplier) are working to connect startups directly with clinicians early in the process so companies can refine their products before investing millions. Universities often invent the technology—but companies bring it to life Many medical device ideas originate in research labs. Universities typically own the patents and license the technology to startups or companies that can develop and commercialize the product. Programs like the ASU Skysong Innovation Center and Tech Launch Arizona help bridge the gap between research and business. The future of healthcare innovation depends on collaboration Successful medical device innovation requires an ecosystem: • clinicians who identify real problems • engineers who build solutions • investors who fund development • manufacturers who scale production Arizona is building that ecosystem through groups like MDM2 (Medical Device Manufacturing Multiplier) and the Phoenix Bioscience Core.       Podcast Show Notes Guest: Stuart Broyles, PhD LKIN: https://www.linkedin.com/in/stuart-broyles-phd/   Stuart builds connections that move ideas forward—from university research to real-world MedTech solutions. He was at WL Gore & Assoc. for nearly 3 decades working in MedTech at various levels and helped bring 13 devices to market. Also includes, university advisory roles, early-stage venture coaching, and innovation ecosystem development. Organization: MDM2 (Medical Device Manufacturing Multiplier) Episode Topic: How Medical Devices Move from Clinical Need to Market   Interview recorded: March 2026 Segment 1 – The Medical Device Industry What Are Medical Devices? Medical devices include a wide range of technologies used to diagnose, monitor, or treat patients. Common examples include: ·         Coronary stents used to treat blocked arteries in the heart ·         Artificial limbs and prosthetics ·         Implantable devices used in cardiology ·         Monitoring technologies such as glucose sensors A well-known example is the glucose monitoring technology produced by Dexcom, which operates in the Mesa, Arizona area. Medical devices also include technologies used to treat circulation issues in arms and legs, along with remote monitoring tools used in modern healthcare. History of the Industry Medical devices began emerging in the 1950s, but the real acceleration occurred between the late 1970s and the 1980s. This era introduced breakthroughs such as: ·         Coronary stents ·         Artificial hearts ·         Prosthetic limbs Over time, the technologies have become: ·         safer ·         more durable ·         more precise Phoenix as a MedTech Hub The Phoenix metro area has developed into a significant medical device and bioscience ecosystem. Major companies with a presence in the region include: ·         Medtronic ·         Abbott Laboratories ·         Dexcom ·         West Pharmaceutical Services This sector is particularly important in the Phoenix Valley, which has a rapidly aging population, increasing demand for medical technology and healthcare innovation. Importance of Clinical Partnerships Successful medical device development requires close collaboration with clinicians and hospitals. In the Phoenix ecosystem, companies often partner with: ·         HonorHealth ·         Mayo Clinic Universities also play a major role in research and collaboration, including: ·         Arizona State University ·         University of Arizona Clinicians provide feedback during development, helping companies ensure devices actually solve real-world clinical problems. How Long It Takes to Bring a Device to Market Development timelines vary widely: Typical timelines: ·         6 months – fastest case observed ·         1 year – simple device pathways ·         Up to 10 years – complex devices requiring clinical trials Segment 2 – Stuart Broyles' Career Stuart Broyles spent nearly 30 years at W. L. Gore & Associates (1995–2024). During that time he worked on multiple divisions developing cardiovascular and medical technologies. Key accomplishments include: ·         Participating in the commercialization of 13 medical devices ·         Working at the team member and leadership levels ·         Bringing complex devices through development and into the market Transition to Mentoring and Innovation After retiring in 2024, Broyles: ·         Did consulting and investing ·         Returned to the startup ecosystem ·         Became an Entrepreneur-in-Residence at Arizona State University He now works with startups through MDM2 (Medical Device Manufacturing Multiplier) helping early-stage companies navigate the development and commercialization process. Many of the companies he works with range from: ·         very early-stage startups ·         teams of just two or three founders ·         companies developing new medical manufacturing technologies MDM2 also partners with HonorHealth to help startups engage with clinical partners. Phoenix Innovation Infrastructure Several organizations contribute to the Valley's health technology ecosystem: Research and innovation hubs ·         Phoenix Bioscience Core ·         Flinn Foundation Startup programs ·         WearTech Center ·         ASU Skysong Innovation Center Medical device and engineering companies ·         PADT (3D printing and product development) ·         BD (Becton Dickinson) Wearable Technology Innovation The WearTech Center in central Phoenix supports startups building wearable medical technologies. Examples include companies such as: ·         Gravitrex ·         Hemasense One demonstration project includes a mock apartment designed to test monitoring systems for independent living seniors, helping companies validate technology in real-world environments. WearTech also hosts quarterly demo days where startups present their technologies to investors and industry partners. Segment 3 – Clinical Trials and Product Development The Need for a "Clinical Innovation Sandbox" A major challenge for startups is access to clinicians who can provide meaningful feedback during early development. MDM2 is working to create a system where: ·         startups can regularly meet clinicians ·         products can be demonstrated in person ·         real clinical feedback is gathered early This helps companies determine whether a product actually solves a meaningful healthcare problem. Continuing Medical Education (CME) Forums MDM2 is developing CME forums that allow clinicians to: ·         learn about emerging medical technologies ·         discuss product concepts ·         provide guidance during early development These sessions also create opportunities for honest feedback before expensive trials begin. One of the first sessions included collaboration with: ·         HonorHealth ·         Hemasense Clinical Trials Outside the United States Clinical trials in the U.S. can be complex and slow due to regulatory requirements. As a result: ·         many companies run trials in Europe or Asia ·         approval processes may be faster ·         testing costs may be lower Improving regulatory efficiency in the U.S. remains a challenge for medical device innovators. Intellectual Property and Universities Many medical technologies originate in universities. In these cases: ·         the university typically owns the intellectual property ·         companies license the technology to commercialize it Technology transfer organizations help bridge the gap between research and commercialization. Programs supporting this in Arizona include: ·         ASU Skysong Innovation Center ·         Tech Launch Arizona These programs help connect professors with entrepreneurs who have experience bringing products to market. Segment 4 – The Future of Medical Device Innovation in Phoenix Phoenix and Arizona are increasingly positioned as a national hub for bioscience and medical device innovation. Key advantages include: ·         strong manufacturing capabilities across the state ·         major university research centers ·         growing healthcare systems ·         startup accelerators and incubators New startups frequently spin out of larger companies like: ·         W. L. Gore & Associates ·         Medtronic These larger companies sometimes help fund and mentor new ventures. Building a Strong Innovation Ecosystem A successful innovation ecosystem requires collaboration among: ·         universities ·         hospitals ·         manufacturers ·         investors ·         startups Arizona is actively building this network to support long-term growth in the medical technology sector. Advice for Entrepreneurs For founders looking to build a medical device startup: 1.    Work with clinicians early in development 2.    Validate the problem you are solving 3.    Understand the regulatory pathway 4.    Build partnerships with universities and hospitals 5.    De-risk the concept before large investments Ultimately, success depends on proving value to three key stakeholders: ·         clinicians ·         investors ·         patients Organizations Mentioned Medical Device Manufacturing Multiplier MDM2 (Medical Device Manufacturing Multiplier)https://www.mdm2.org/ MDM2 works to strengthen Arizona's medical device manufacturing ecosystem through partnerships with universities, hospitals, and startups. WearTech Center WearTech Centerhttps://www.azweartech.org/projects Focus areas include: ·         wearable health technologies ·         remote monitoring systems ·         aging-in-place innovations   If you want to learn more about the growing medical device ecosystem in Arizona, visit the website for the MDM2 (Medical Device Manufacturing Multiplier) and explore how they're helping startups move innovations from the lab to the patient.     Tech Topic: https://brt-show.libsyn.com/category/Tech-Startup-VC-Cybersecurity-Energy-Science  Best of Tech: https://brt-show.libsyn.com/size/5/?search=best+of+tech   'Best Of' Topic: https://brt-show.libsyn.com/category/Best+of+BRT      Thanks for Listening. Please Subscribe to the AZ TRT Podcast.     AZ Tech Roundtable 2.0 with Matt Battaglia The show where Entrepreneurs, Top Executives, Founders, and Investors come to share insights about the future of business.  AZ TRT 2.0 looks at the new trends in business, & how classic industries are evolving.  Common Topics Discussed: Startups, Founders, Funds & Venture Capital, Business, Entrepreneurship, Biotech, Blockchain / Crypto, Executive Comp, Investing, Stocks, Real Estate + Alternative Investments, and more…    AZ TRT Podcast Home Page: http://aztrtshow.com/ 'Best Of' AZ TRT Podcast: Click Here Podcast on Google: Click Here Podcast on Spotify: Click Here                    More Info: https://www.economicknight.com/azpodcast/ KFNX Info: https://1100kfnx.com/weekend-featured-shows/  

Tom Looby, CEO of Conavi, is focused on developing hybrid intravascular imaging technology that combines two established modalities into a single imaging catheter to provide a comprehensive view of the coronary arteries. This eliminates blind spots when using either intravascular ultrasound (IVUS) or optical coherence tomography (OCT) alone and is driving a shift away from relying solely on traditional angiography toward the use of advanced intravascular imaging to guide coronary procedures. Using AI to analyze dual-stream co-registered data allows interventional cardiologists to more accurately assess lesions, determine the appropriate stent size, and ensure proper placement, thereby reducing cardiac death and blood clots around stents. Tim explains, "So our technology is an imaging catheter. We're unique in that we combine two imaging modalities that are already well established in the market. But because each of them has blind spots, by combining them into a single catheter, we remove those blind spots, and we think we produce the best imaging catheter to help guide coronary interventions."   "It is well known that these strengths and weaknesses occur in both ultrasound and optical imaging. But to set the stage, this is a trend happening in the marketplace. There are four million angioplasty stenting procedures performed each year, and most of them rely solely on traditional angiography. Most of your audience probably knows that angiography is an X-ray that uses a contrast agent, so you're seeing the vasculature around the heart through a secondary image. The detailed view inside the blood vessels is limited when using only angiography, which has restricted the types of procedures doctors have been able to perform over time. Recognizing that intravascular ultrasound, sometimes called IVUS, and separately, OCT—short for optical coherence tomography—were developed independently to examine inside the blood vessel." #Conavi #CardiovascularImaging #InterventionalCardiology #MedicalDevice #HeartHealth #Innovation #IVUS #OCT #AIinHealthcare #CardiacIntervention #HealthTech #Medtech #Cardiology #HybridImaging Conavi.com Download the transcript here  

Tom Looby, CEO of Conavi, is focused on developing hybrid intravascular imaging technology that combines two established modalities into a single imaging catheter to provide a comprehensive view of the coronary arteries. This eliminates blind spots when using either intravascular ultrasound (IVUS) or optical coherence tomography (OCT) alone and is driving a shift away from relying solely on traditional angiography toward the use of advanced intravascular imaging to guide coronary procedures. Using AI to analyze dual-stream co-registered data allows interventional cardiologists to more accurately assess lesions, determine the appropriate stent size, and ensure proper placement, thereby reducing cardiac death and blood clots around stents. Tim explains, "So our technology is an imaging catheter. We're unique in that we combine two imaging modalities that are already well established in the market. But because each of them has blind spots, by combining them into a single catheter, we remove those blind spots, and we think we produce the best imaging catheter to help guide coronary interventions."   "It is well known that these strengths and weaknesses occur in both ultrasound and optical imaging. But to set the stage, this is a trend happening in the marketplace. There are four million angioplasty stenting procedures performed each year, and most of them rely solely on traditional angiography. Most of your audience probably knows that angiography is an X-ray that uses a contrast agent, so you're seeing the vasculature around the heart through a secondary image. The detailed view inside the blood vessels is limited when using only angiography, which has restricted the types of procedures doctors have been able to perform over time. Recognizing that intravascular ultrasound, sometimes called IVUS, and separately, OCT—short for optical coherence tomography—were developed independently to examine inside the blood vessel." #Conavi #CardiovascularImaging #InterventionalCardiology #MedicalDevice #HeartHealth #Innovation #IVUS #OCT #AIinHealthcare #CardiacIntervention #HealthTech #Medtech #Cardiology #HybridImaging Conavi.com Listen to the podcast here  

Full article: https://www.ajronline.org/doi/10.2214/AJR.25.34334  The PET/CT examinations commonly obtained in patients with cancer provide additional information that can be used for nononcologic prognostication. Radhika Rajeev, MD, discusses the AJR article by Kim et al. exploring the role of visual ordinal coronary calcium scoring on routine FDG PET/CT examinations in predicting perioperative outcomes.

Welcome to this podcast from the Medical Journal of Australia. My name is Sally Block, the MJA's news and online editor.  “The MJA acknowledges the Traditional Owners and Custodians of the land on which we live and work across Australia.  This podcast was recorded on the lands of the Gadigal people of the Eora Nation  I pay my respects to their Elders past and present.” The MJA has recently published the Australian Clinical Guideline for Diagnosing and Managing Acute Coronary Syndromes 2025. Professor Garry Jennings AO has a distinguished career as a cardiologist in clinical practice and was previously Director of Cardiology at The Alfred Hospital, Melbourne, and Chair of the Division of Medicine. He is the Heart Foundation's Chief Medical Advisor. Professor Jennings is a co-author of the Guideline and joins me now.

Stephen is a Carnivore & Keto Coac, Specialist Practitioner in Obesity & Diabetes, Personal Trainer, and Qualified Phlebotomist for blood tests

Heart disease kills one person every 40 seconds. That number hasn't changed in 30 years. Dr. John Osborne, a preventive cardiologist with two doctorates and 29 years in practice, has spent his career on a single question: why do we screen for cancers that kill a few percent of us and do nothing for the disease that kills 40%? In this episode, Jeremy and Jason sit down with Dr. Osborne to get the real story on cardiac CT with AI — the imaging technology that can detect, quantify, and track arterial plaque at sub-millimeter resolution, years before symptoms appear. If you track your bloodwork, wear a fitness device, or consider yourself health-forward — this is the conversation that fills the gap nobody warned you about.Guest Link:https://clearcardio.com/Key Moments:00:00 — Dr. Osborne's case for preventive cardiology: why heart disease is the most under-screened killer02:43 — How cardiac CT evolved from "iPhone 0.5" to the 2026-era AI-powered tool he uses today05:35 — Why he gave up stress tests and heart caths in 2005 and never looked back08:16 — What AI actually adds: seeing and quantifying plaque invisible to the human eye, down to 0.1 cubic millimeters10:13 — When insurance pays for cardiac CT — and when it doesn't (the preventive gray zone)14:50 — The “cardiac colonoscopy” concept: the case for screening before symptoms, not after18:11 — Coronary artery calcium score: the accessible $100 starting point, and what it can and can't tell you31:54 — Lifestyle essentials: the 50% of risk that's modifiable regardless of genetics35:00 — Family history decoded: why your sibling's heart history matters more than your parents'36:12 — Nicotine myth-busting: Dr. Osborne on the "health guru" nicotine fad and why he thinks it's dangerous38:05 — Supplements under scrutiny: natokinase, fish oil, red yeast rice — what the actual RCT data says

With Morton Kern, VA Long Beach and University of California, Irvine, California - USA and Arnold Seto, VA Long Beach and University of California, Irvine, California - USA. Link to European Heart Journal paper Link to European Heart Journal editorial

Lipids remain central to cardiovascular prevention. The 2026 ACC/AHA Dyslipidemia Guideline introduces several important shifts:   • PREVENT equations replace older ASCVD risk calculators • Lipoprotein(a) measurement recommended at least once in all adults • ApoB helps identify residual lipoprotein risk • Coronary artery calcium scoring refines treatment decisions • LDL-C targets return, with

Episode 215: Meth-associated HFrEF.   Abishak and Zat (medical students) explain the cardiotoxic effect of methamphetamine and the diagnosis and treatment of heart failure with reduced ejection fraction (HFrEF). Dr. Arreaza adds insight into the reversibility of meth-associated HFrEF.   Written by Abishak Govindarajan, MSIV and Zat Akbar Shaw. American University of the Caribbean. Edits and comments by Hector Arreaza, MD. Welcome Dr. Arreaza: Welcome to Rio Bravo qWeek. My name is Hector Arreaza, family physician, faculty and associate program director of the Clinica Sierra Vista/Rio Bravo Family Medicine Residency Program. Today we will explore heart failure with reduced ejection fraction, a high-yield and clinically relevant topic in medicine. We will discuss the role of methamphetamine use in the development of HFrEF. This is a pressing issue because about 0.8% of the population 12 and older in the US reported using methamphetamine within the past 12 months in 2024 (National Survey on Drug Use and Health, NSDUH), that's about ≈2.4 million people!We are joined by two aspiring physicians who will help explore this topic. By the way, we will refer to methamphetamine in this episode as “meth”. [Abishak and Akbar introduce themselves] Abishak: [Introduce yourself] The role of meth in HFrEF Dr. Arreaza: Meth is a growing problem in many places, including Bakersfield, where we live. Meth is also known as Meth Crystal, Poor man's cocaine, Ice, Glass, Crank, Speed, Chalk, and Tina. How does meth contribute to the development of HFrEF? Abishak: So, first, let's understand how methamphetamine works. It has a chemical structure similar to dopamine and norepinephrine, and it gets taken up through the neuron transporter proteins. Once it enters the synaptic vesicles (storage sacs for neurotransmitters), it displaces and forces the release of large amounts of dopamine, norepinephrine, and serotonin into the synapse (the space between neurons). Additionally, meth blocks the reuptake of those neurotransmitters into the neuron, ensuring they remain in the synapse for a prolonged period. All this causes a downstream effect of increased sympathetic pathways in the body. Diagnosis Dr. Arreaza: The diagnosis starts with collecting a good history and performing a complete physical exam, and then we confirm with an echocardiogram.  Abishak: Yes, diagnosis requires both symptoms consistent with heart failure and objective evidence of reduced ejection fraction. Echocardiography is the primary diagnostic tool. We also measure BNP. In certain cases, cardiac MRI is used to evaluate myocardial fibrosis and exclude infiltrative or inflammatory etiologies. Coronary angiography may be performed if ischemic disease is suspected.Guideline-Directed Medical Therapy Dr. Arreaza: GDMT Guideline-Directed Medical Therapy started around 1987 when ACE inhibitors were proven to improve mortality in patients with heart failure. Then, during the following decades, many medications have been added to GDMT. Until around 2019–2022 we came out with the main 4 groups of medications that we know as GDMT. Let's talk about GDMT. Akbar: There are four core pillars in GDMT. First, an angiotensin receptor-neprilysin inhibitor, such as sacubitril with valsartan (Entresto), is preferred over ACE inhibitors when tolerated. This medication reduces mortality and heart failure hospitalizations. Second, evidence-based beta blockers including carvedilol, metoprolol succinate, or bisoprolol are used to reduce sympathetic overactivity and improve ventricular remodeling. Third, mineralocorticoid receptor antagonists such as spironolactone or eplerenone reduce fibrosis and improve survival. The Fourth pillar is SGLT2 inhibitors such as dapagliflozin or empagliflozin, which provide significant reductions in heart failure hospitalizations and cardiovascular mortality, regardless of diabetes status. Abishak: Other main parts of the treatment are diuretics, which are used for symptom control but do not reduce long-term mortality. Dr. Arreaza: As a recap: The current 4 pillars of GDMT are: ARNI/ACEi + β-blocker + MRA + SGLT2i)  Beta Blocker Considerations Dr. Arreaza: Sometimes we may be concerned about using beta blockers in active meth users. What did you read about it? Abishak: Historically, there was concern about unopposed alpha stimulation. However, in chronic heart failure, beta blockers remain essential. Carvedilol is often favored because it provides both alpha and beta blockade. Careful titration and close monitoring are critical.Reversibility and Remodeling Dr. Arreaza: Regarding meth-associated HFrEF, we have good news for meth users. Tell us about how reversible this condition is.  Akbar: It can be reversible. One of the most important aspects of this condition is that significant reverse remodeling may occur if the patient stops methamphetamine use and adheres to medical therapy. The Left ventricular ejection fraction can improve substantially and, in some cases, normalize. On the other end of the spectrum, continued meth use may lead to progressive fibrosis, ventricular dilation, and potentially irreversible damage, leading to death.Complications of meth-associated HFrEF Abishak: These patients are at increased risk for ventricular arrhythmias, sudden cardiac death, left ventricular thrombus formation, and progressive pulmonary hypertension. If the ejection fraction remains below 35 percent after at least three months of optimized therapy, implantable cardioverter-defibrillator (known as ICD) placement should be considered for primary prevention.Addiction Treatment as Core Therapy Dr. Arreaza: It sounds like GDMT cannot be done without talking about meth use disorder treatment. Akbar: Absolutely. Treating the myocardium without addressing the substance use disorder is ineffective. Primary care providers can be trained to manage addictions, but if resources are available, you can place a referral to addiction medicine, psychiatric support, behavioral therapy, and social support services. This is an essential part of the treatment. Sustained abstinence is the single most powerful predictor of recovery.Prognosis Abishak: Prognosis is highly dependent on abstinence. Patients who stop using methamphetamine often experience meaningful improvement in EF and even return to normal.  Dr. Arreaza: Yes, the key factor is complete abstinence, plus standard heart failure treatment. If the damage is mostly functional and inflammatory, recovery is possible. If there is extensive fibrosis (scar) recovery is less likely. Observational studies have shown that patients with meth-associated cardiomyopathy who stop using meth have significant improvement in EF over 3–12 months, fewer hospitalizations, and lower mortality. Akbar: Absolutely. Not all meth-associated cardiomyopathy behaves the same way. The extent of fibrosis determines recovery potential. Cardiac MRI with late gadolinium enhancement can help us estimate scar burden. Patients with minimal fibrosis often have better improvement with abstinence and medical therapy. Dr. Arreaza: So, MRI can actually help us determine the prognosis. Abishak: Yes, very much so. If MRI shows extensive fibrosis, the likelihood of full EF recovery is lower. That information helps us counsel patients more accurately. Akbar: Another key issue is right ventricular involvement. Methamphetamine can affect both ventricles. When the right ventricle fails, patients may develop severe peripheral edema, ascites, and hepatic congestion. Right ventricular dysfunction also worsens prognosis significantly. Dr. Arreaza: And pulmonary hypertension can also worsen the whole picture.  Akbar: That's correct. Meth is associated with pulmonary arterial hypertension independently of left-sided heart failure. In some patients, you may see a combined picture of both pulmonary vascular disease and right ventricular dysfunction. That can make management more complicated because pulmonary pressures may remain elevated even after EF improves. Dr. Arreaza: Tells us about the role of BNP in monitoring these patients.  Abishak: Serial BNP levels can help track response to therapy. Additionally, troponin may be elevated at times in meth users due to myocardial injury. Monitoring renal function is critical because many heart failure medications affect kidney function and potassium levels. Akbar:Other lifestyle modifications include sodium restriction, regular follow-ups, vaccination, and avoidance of other cardiotoxic substances such as alcohol or cocaine. Sleep disorders, especially OSA, should be evaluated because untreated OSA worsens heart failure outcomes. Dr. Arreaza: WhatIs there any role for wearable devices or remote monitoring? Abishak: Yes, increasingly so. Remote weight monitoring, blood pressure tracking, and symptom reporting can reduce hospitalization. In select patients, implantable hemodynamic monitors may help detect rising filling pressures before symptoms occur. Dr. Arreaza: It was a great discussion. Thank you, Abishak and Akbar for bringing all that valuable information to us. Let's wrap it up.     

Laura Beaton chats with David Brieger, head of cardiology at Concord Hospital, Sydney, about the 2025 Australian acute coronary syndromes [ACS] clinical guideline. David explains the importance of secondary prevention for ACS, including new approaches to tailoring the duration of dual antiplatelet therapies, new lipid targets, and the limited role of beta blockers and colchicine. Read the full article in Australian Prescriber.

In this episode, Sam Ashoo, MD and T.R. Eckler, MD discuss the February 2026 Emergency Medicine Practice article, Emergency Department Diagnosis and Management of Acute Coronary Occlusion00:00 - Introduction & Welcome01:21 - Episode Overview: Acute Coronary Occlusion02:06 - Why This Topic Matters: Statistics & New Guidelines03:35 - Nomenclature: ACO vs STEMI/NSTEMI06:15 - Differential Diagnosis for STEMI07:41 - Pre-Hospital Care & EMS Role11:37 - Patient History & Presenting Symptoms12:28 - Physical Examination Findings14:54 - EKG: The Most Important Test17:00 - STEMI Definition & Criteria20:32 - STEMI Equivalents: Scarbosa Criteria22:40 - Smith Modified Scarbosa Criteria24:10 - Hyperacute T Waves25:30 - Posterior STEMI28:40 - De Winter Sign29:38 - Non-STEMI EKG Findings31:30 - AVR ST Elevation32:47 - Wellens Syndrome33:54 - Reciprocal ST Segment Changes36:15 - Inferior MI Patterns37:54 - Laboratory Testing39:51 - Imaging: Chest X-Ray & Echocardiography42:25 - Supplemental Oxygen: What the Evidence Shows44:50 - Analgesia & Pain Management46:35 - Pharmacotherapy: Aspirin & Antiplatelet Agents49:18 - Reperfusion Therapies & Thrombolytics53:05 - Cardiac Arrest in STEMI Patients53:55 - Closing Remarks & CME InformationSubscribers, take the CME test here.Emergency Medicine Residents, get your free subscription by writing resident@ebmedicine.net

Dr. Linda Chu speaks with Dr. Kavitha Chinnaiyan and Dr. Jonathon Leipsic about why 2026 marks an inflection point for coronary CT, from AI-enabled plaque quantification to FFR-CT and evolving guideline support for CT-first evaluation of suspected coronary artery disease. They explore how advanced imaging tools are reshaping risk assessment, personalizing prevention and revascularization decisions, and strengthening collaboration between radiology and cardiology while highlighting the need for validation, standardization, and equitable access.

For decades, healthcare has trained us to wait. Wait for symptoms. Wait for abnormal labs. Wait for a crisis. In this powerful conversation, Dr. Robert Todd Hurst, MD, FACC, FASE sits down with membership medicine pioneer Tom Blue to unpack why that model is failing, and what's replacing it. Together, they explore the rise of proactive, precision-based care, why insurance is misaligned with true prevention, how technology is compressing the 17-year “translational gap” in medicine, and what it really takes to build a “medical time machine.” They also dive into cognitive longevity, artificial intelligence in healthcare, and why your health is no longer destiny…it's a skill set. If you've ever wondered why traditional healthcare feels rushed, reactive, and one-size-fits-all… this episode explains why, and shows you a better path forward.   About Our Guest: Tom Blue Tom Blue is one of the most influential voices in membership-based medicine and modern healthcare innovation. For over two decades, he has helped physicians build practices centered on prevention, personalization, and patient experience, long before it became mainstream. Through his work at OvationLab, Tom partners with forward-thinking doctors to compress the gap between medical discovery and real-world care. His passion? Turning cutting-edge science into practical systems that help people live longer, sharper, stronger lives.   Connect with Tom Blue:  

In this episode of the Heart podcast, Digital Media Editor Professor James Rudd is joined by Dr Craig Balmforth from the University of Edinburgh. They discuss the rationale for identifying high-risk plaque, how imaging can help, and emerging therapies, including PCI. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks! Link to published paper: https://heart.bmj.com/content/112/1/13.long

Cholesterol can look “normal” and you can still have plaque.In this episode, we break down proactive heart disease screening before a heart attack or stroke—starting with the coronary calcium score test and when to consider coronary CT angiography (CTA). We explain why prevention shouldn't rely on a basic lipid panel alone, and how risk factors like family history, diabetes, and borderline labs may justify earlier imaging.You'll learn what a coronary calcium score does (and doesn't) show, and how advanced CTA plaque analysis helps visualize plaque, measure type and volume, and assess true cardiovascular risk—not just estimate it.If you're wondering whether you should be screened due to genetics or early heart disease in your family, this conversation helps you understand the right questions to ask a qualified provider.Share this with someone who needs it. For more information on heart disease prevention and screening options, reach out through our website.Timestamps00:00 – Why reactive healthcare fails 00:27 – Preventing heart attacks before they happen 00:44 – Why waiting for chest pain is too late 02:16 – Risk factors vs. actual plaque 03:18 – Coronary calcium score explained 03:41 – What is coronary CTA plaque analysis? 05:06 – Measuring plaque type and volume 06:50 – Who should screen earlier 09:59 – Who benefits most from proactive prevention 12:43 – Calcium score: screening vs. monitoring 16:52 – Women & soft plaque limitations 20:18 – Treat heart disease a decade earlyLearn More: https://www.alluremedical.com/Books & Research: https://www.alluremedical.com/books/Follow Dr. Charles Mok & Allure Medical: LinkedIn: https://www.linkedin.com/in/charles-mok-4a0432114/ Instagram: https://www.instagram.com/alluremedicals/ YouTube: https://www.youtube.com/@AllureMedical TikTok: https://www.tiktok.com/@alluremedicalAmazon Store: https://www.amazon.com/stores/Dr.-Charles-Mok/author/B0791M9FZQInner Circle Membership: https://www.alluremedic#insidethecure

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial septal defects in adults Conservative and invasive management of chronic coronary syndromes Milestones: 4S trial   Host: Rick Grobbee Guests: JP Carpenter, Annemien van den Bosch, Rasha Al-Lamee, Roxana Mehran Want to watch the episode? Go to: https://esc365.escardio.org/event/2552 Want to watch the extended interview on Atrial septal defects in adults, go to: https://esc365.escardio.org/event/2552?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel and Annemien van den Bosch have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Rasha Al-Lamee has declared to have potential conflicts of interest to report:speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir, Astrazeneca. Consulting Fees: Menarini pharmaceuticals, Abbott, Philips, Shockwave, Elixir, IsomAB, VahatiCor, SpectraWave, AstraZeneca, Cathworks, Janssen Pharmaceuticals. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Roxana Mehran has declared to have potential conflicts of interest to report: institutional research payments from Abbott, Alleviant Medical, Chiesi, Concept Medical, Cordis, CPC Clinical Research, Daiichi Sankyo, Duke, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, Medtronic, NewAmsterdam Pharma, Novartis, Novo Nordisk Inc., Population Health Research Institute (PHRI), Protembis GmbH, Radcliffe, RM Global Bioaccess Fund Management, Sanofi US Services, Inc. ; personal fees from: None ; Equity

Heart disease risk isn't just about cholesterol. In this episode of A Whole New Level, Dr. Matthew Budoff explains why coronary artery calcium (CAC) scoring may be the most important test most people aren't getting—and why imaging your arteries directly can reveal risk that blood tests alone can miss.Drawing on decades of research and data from the landmark MESA study, Dr. Budoff explains how calcium scoring predicts real cardiovascular events, how plaque actually forms and progresses, and why some people with high cholesterol never develop plaque—while others with “normal” labs do.This episode focuses on how to measure your actual cardiovascular risk, not just estimate it.Sign Up to Get Your Free Ultimate Guide to Glucose: ⁠https://levels.link/wnlIn this episode, we cover:Why CAC scoring is one of the strongest predictors of future heart eventsWhy cholesterol is critical—but only explains about half of heart disease riskWhy some people with very high LDL have zero plaque—and others with normal labs have dangerous plaqueWhy CAC is best understood as the “tip of the iceberg” of total plaque burdenWhen to escalate to CT angiography and advanced imagingHow plaque regression is possible—and what interventions actually drive itThe future of cardiac risk prediction: Lp(a), inflammation, and AI-driven plaque analysisThis conversation reframes heart risk around what's actually happening inside your arteries—not just what shows up in bloodwork.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Would like like to share feedback on this podcast? Or suggest another topic for us to explore? Click here, or email us at DocTalk@medstar.netFor more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Join Digital Education Committee Chair and podcast host Michael S. Lloyd, MD, FHRS, and his guests Kelvin C. Chua, MBBS, MD, FHRS, CEPS-A, and Rahul N Doshi, MD, FHRS, for this week's Lead episode, which was recorded live at APHRS 2025 in Kyoto, Japan. This discussion will review recent evidence on the feasibility and safety of pulsed field ablation (PFA) for coronary sinus and left atrial appendage isolation, as well as mitral isthmus ablation, focusing on both acute and chronic outcomes. Panelists will examine procedural considerations, lesion durability, and safety signals highlighted in the study, and explore how these findings may inform evolving ablation strategies for complex atrial arrhythmias.   Learning Objectives Summarize the acute and chronic feasibility and safety outcomes of pulsed field ablation (PFA) for coronary sinus isolation, left atrial appendage isolation, and mitral isthmus ablation as reported in the study. Evaluate procedural techniques and lesion durability considerations associated with using PFA in anatomically complex atrial structures. Assess the potential clinical implications of these findings for incorporating PFA into ablation strategies for complex atrial arrhythmias, including patient selection and risk mitigation.   Podcast Contributors Michael S. Lloyd, MD, FHRS Kelvin C. Chua, MBBS, MD, FHRS, CEPS-A Rahul N Doshi, MD, FHRS   Host and Contributor Disclosure(s): K.C. Chua•Nothing to disclose. R. N. Doshi•Speaking/Teaching/Consulting/Authoring: Boston Scientific, Kestra Inc., Abbott, Impulse Dynamics USA    M. S. Lloyd •Honoraria/Speaking/Consulting: Medtronic, Agra MedTech, Circa Scientific •Membership on Advisory Committees: Boston Scientific   Article for Discussion

JHLT: The Podcast returns with an episode discussing the paper, "Impact of evolocumab on coronary physiology and microstructure in de-novo heart transplant recipients," from the January issue of JHLT. Featured on this episode is early career guest host Bin Yang, MD, of Massachusetts General Hospital. Mentored by Digital Media Editor Van-Khue Ton, MD, PhD, Dr. Yang shares hosting duties this episode and brings great questions to the discussion. Drs. Yang and Ton are joined by the first author, Salma Karim, and senior author, Hans Eiskjaer, both from Aarhus University Hospital in Denmark. The discussion explores: What imaging and physical markers the researchers used to determine if evolocumab was influencing the development of cardiac allograft vasculopathy (CAV) The potential role of lipid-lowering therapies or statins in treating CAV The relationship between CAV and microvascular resistance (IMR) For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. In case you missed it, earlier this month the JHLT Digital Media Editors recapped their favorite papers from 2025. Take a listen! Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Dr Aernoud Fiolet from Utrecht in the Netherlands. They discuss the imaging substudy of the LoDoCo2 trial, which tested colchicine in patients with chronic coronary syndromes. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks! Link to published paper: https://heart.bmj.com/content/111/23/1156.long  

My 30+ years of involvement with CT heart scans and coronary calcium scores has yielded many important lessons on how to halt, then reverse, the accumulation of coronary atherosclerotic plaque and thereby risk for heart attack, need for heart procedures, and sudden cardiac death.Here, I discuss the crucial importance of vitamin D and how, by addressing this issue, it was the first time I saw actual reductions in coronary calcium scores. Support the showYouTube channel: https://www.youtube.com/@WilliamDavisMD Blog: WilliamDavisMD.com Membership website for two-way Zoom group meetings: InnerCircle.DrDavisInfiniteHealth.com Books: Super Gut: The 4-Week Plan to Reprogram Your Microbiome, Restore Health, and Lose Weight Wheat Belly: Lose the Wheat, Lose the Weight and Find Your Path Back to Health; revised & expanded ed

What do you think of serrapeptase for reducing coronary plaque?We were told to get a TDAP vaccine or we wouldn't be able to see our new grandchild for 8 weeks!Do I have lupus?Which supplements tend to reduce negative effects of X-rays?

Former interventional cardiologist Dr. William Davis left traditional cardiology after his mother died months after a successful angioplasty. What he discovered challenges everything mainstream medicine teaches about heart disease.Standard cholesterol testing is outdated. The real drivers of cardiovascular disease are small LDL particles created by wheat, grains, and sugars, amplified by gut microbiome disruption. Coronary calcium scores predict heart attacks far better than cholesterol levels, yet conventional treatments like statins show zero impact on plaque progression.Dr. Davis reveals how antibiotic overuse has left half the US population with small intestinal bacterial overgrowth, driving not just digestive issues but heart disease, obesity, autoimmune conditions, and neurological decline. Eliminating wheat and grains while restoring beneficial bacteria like Lactobacillus reuteri can make dangerous particles disappear.He also exposes the dangers of conventional weight loss: calorie restriction causes 25% muscle loss, permanently slowing metabolism and leading to early death despite temporary improvements. His new book Superbody offers an alternative focused on muscle preservation and microbiome restoration.This conversation fundamentally reframes how diet, gut health, and heart disease connect.Contact Info : Dr. William Davis - Facebook: https://www.facebook.com/drwilliamdavishealth/ Website: williamdavismd.com LinkedIn: https://www.linkedin.com/in/drwilliamdavis/ Follow Dr. Ovadia: Twitter: @iFixHearts Website: OvadiaHeartHealth.com Metabolic Health Quiz: iFixHearts.com Send Dr. Ovadia a Text Message. (If you want a response, you must include your contact information.) Dr. Ovadia cannot respond here. To contact his team, please send an email to team@ifixhearts.com Like what you hear? Head over to IFixHearts.com/book to grab a copy of my book, Stay Off My Operating Table. Ready to go deeper? Talk to someone from my team at IFixHearts.com/talk.Stay Off My Operating Table on X: Dr. Ovadia: @iFixHearts Jack Heald: @JackHeald5 Learn more: Stay Off My Operating Table on Amazon Take Dr. Ovadia's metabolic health quiz: iFixHearts Dr. Ovadia's website: Ovadia Heart Health Jack Heald's website: CultYourBrand.com Theme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

In this episode, Dr. Amro Alsaid, Medical Director of Advanced Cardiac Imaging, and Dr. Karim Al-Azizi, Medical Director of the Catheterization Laboratory and Structural Heart Program at Baylor Scott & White The Heart Hospital, discuss how AI and advanced cardiac imaging are reshaping coronary diagnosis, improving precision in patient care, and optimizing workflow efficiency across cardiology programs.Visit Cleerly Health to learn more. https://cleerlyhealth.com/what-is-cleerly?utm_campaign=cleerly_brand&utm_medium=podcast&utm_source=beckers&utm_content=pr-podcast-11-2025

“I think everyone should have Lp(a) measured.”  - Dr. Ann Marie Navar   Key Resources to Go Deeper:  - Dr. Ann Marie Navar  - Lp(a)  - Get a Free Test to Check Your Lp(a) Level   - Previous episode with Dr. Navar about ApoB  About This Episode:  Listen to this replay of an important discussion about Lipoprotein(a), or Lp(a), a critical but often overlooked marker for cardiovascular health. In this episode, host Barbara Hannah Grufferman takes a deep dive with medical expert Dr. Ann Marie Navar from UT Southwestern Medical Center about why this single test could be vital for understanding your heart disease risk, especially if you have a family history of early cardiovascular disease.  Key Topics Covered:  - What Lipoprotein(a) is and how it differs from standard cholesterol measurements  - Why Lp(a) testing is particularly important for certain individuals  - The genetic nature of Lp(a) and its implications for family health  - Current treatment options and promising new therapies on the horizon  - Practical steps for discussing Lp(a) testing with your healthcare provider  Key Takeaways:  - Lp(a) is a distinct type of cholesterol particle not captured in routine lipid panels  - High Lp(a) levels significantly increase risk of heart disease and stroke  - Lp(a) levels are primarily determined by genetics and remain stable throughout life  - Current guidelines recommend universal Lp(a) testing for adults  - New treatments specifically targeting high Lp(a) levels are expected by 2026  - Managing other risk factors can help offset the risk of elevated Lp(a)  - Coronary artery calcium scoring can provide additional risk assessment  Learn More About Dr. Ann Marie Navar  Dr. Navar is a preventive cardiologist and epidemiologist at UT Southwestern Medical Center whose research focuses on cardiovascular disease prevention, risk prediction, and clinical decision-making. She is a leading expert in advanced lipid testing and cardiovascular risk assessment. This is Dr. Navar's second appearance on AGE BETTER, following her previous discussion about the ApoB test, which was one of the most down-loaded episodes in 2024.   Connect With Barbara:  Have ideas for future episodes? We'd love to hear from you!  - Email: agebetterpodcast@gmail.com  - Connect on Instagram HERE  Note: This episode is for informational purposes only and does not constitute medical advice. Please consult with your healthcare provider about your specific situation. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week we review a recent retrospective review from Phoenix Children's Hospital about coronary artery fistulae. How common are they and who needed intervention? How should the cardiologist think about the small fistula? Should they all be ‘followed' or can they be discharged from cardiology follow-up? How small is ‘small enough'? We speak with Dr. Marie Chevenon who is a fetal cardiologist at Phoenix Children's Hospital about her recent study on the Phoenix experience with coronary artery fistulae.  https://doi.org/10.1007/s00246-024-03600-y